


CLAIMS

1. A compound of formula (I):



wherein:

R^1 is C_{1-6} alkoxy (optionally substituted by C_{1-4} alkoxy or phenyl), C_{3-6} alkenyloxy, phenoxy or piperidin-4-yl (1-substituted by $C(O)R^7$ or $S(O)_2R^8$);

R^2 is optionally substituted phenyl, optionally substituted heteroaryl or cycloalkyl;

R^{2a} , R^4 and R^{4a} are, independently, hydrogen or C_{1-4} alkyl;

R^3 and R^{3a} are, independently, hydrogen or C_{1-4} alkyl or C_{1-4} alkoxy;

R^5 is hydrogen, C_{1-4} alkyl (optionally substituted by halogen, hydroxy, C_{1-4} alkoxy, C_{3-7} cycloalkyl, SH, C_{1-4} alkylthio, cyano or $S(O)_q(C_{1-4}$ alkyl)), C_{3-4} alkenyl, C_{3-4} alkynyl or C_{3-7} cycloalkyl;

R^6 is phenyl, heteroaryl, phenylNH, heteroarylNH, phenyl(C_{1-2})alkyl, heteroaryl(C_{1-2})alkyl, phenyl(C_{1-2} alkyl)NH or heteroaryl(C_{1-2} alkyl)NH;

R^7 is C_{1-6} alkyl (optionally substituted by phenyl, heteroaryl, C_{1-4} alkoxy, or C_{1-4} alkoxy(C_{1-4} alkoxy)), C_{1-6} alkoxy, phenyl, heteroaryl or C_{3-6} cycloalkyl;

R^8 is C_{1-6} alkyl (optionally substituted by phenyl) or phenyl;


wherein the phenyl and heteroaryl rings of any of the foregoing are independently optionally substituted by halo, cyano, nitro, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, $S(O)_m C_{1-4}$ alkyl, $S(O)_2 NR^9 R^{10}$, $NHS(O)_2(C_{1-4}$ alkyl), NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl) $_2$, $NHC(O)NH_2$, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), CO_2H , $CO_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 , CHF_2 , CH_2F , CH_2CF_3 or OCF_3 ;

R^9 and R^{10} are, independently, hydrogen or C_{1-4} alkyl, or together with a nitrogen or oxygen atom, may join to form a 5- or 6-membered ring which is optionally substituted with C_{1-4} alkyl, $C(O)H$ or $C(O)(C_{1-4}$ alkyl);

m , p and q are, independently, 0, 1 or 2;

or a pharmaceutically acceptable salt thereof or a solvate thereof.

2. A compound as claimed in claim 1 wherein R¹ is piperidin-4-yl 1-substituted by C(O)R⁷ {wherein R⁷ is C₁₋₆ alkyl (optionally mono-substituted by phenyl), C₁₋₆ alkoxy, phenyl or C₃₋₆ cycloalkyl, wherein the phenyl rings are optionally substituted by halogen} or S(O)₂R⁸ {wherein R⁸ is phenyl or C₁₋₆ alkyl (optionally mono-substituted by phenyl), wherein the phenyl rings are optionally substituted by halogen, S(O)₂(C₁₋₄ alkyl) or NHC(O)(C₁₋₄ alkyl)}, or R¹ is C₁₋₆ alkoxy (optionally substituted by C₁₋₄ alkoxy or phenyl), C₃₋₆ alkenyloxy or phenoxy (optionally substituted by halogen).
3. A compound as claimed in claim 1 or 2 wherein R² is phenyl optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, S(O)_n(C₁₋₄ alkyl) (wherein n is 0, 1 or 2), nitro, cyano or CF₃.
4. A compound as claimed in claim 1, 2 or 3 wherein R^{2a}, R³, R^{3a}, R⁴ and R^{4a} are all hydrogen.
5. A compound as claimed in claim 1, 2, 3 or 4 wherein R⁵ is ethyl.
6. A compound as claimed in claim 1, 2, 3, 4 or 5 wherein R⁶ is benzyl singly substituted by S(O)₂(C₁₋₄)alkyl or S(O)₂NR⁹R¹⁰; wherein R⁹ and R¹⁰ are, independently, hydrogen or C₁₋₄ alkyl, or together with a nitrogen or oxygen atom, may join to form a 5- or 6-membered ring which is optionally substituted with C₁₋₄ alkyl, C(O)H or C(O)(C₁₋₄ alkyl).
7. A process for preparing a compound of formula (I) comprising:
 - a) treating a compound of formula (II):




with:

- i. an acid chloride or chloroformate of formula $R^1C(O)Cl$, in the presence of a base and in a suitable solvent; or

- ii. when R^1 is a 1-substituted piperidin-4-yl, an acid of formula R^1CO_2H in the presence of a suitable coupling agent in a suitable solvent;

OR

- b) reacting a compound of formula (VII):



- i. with an acid chloride $R^7C(O)Cl$ or sulfonyl chloride $R^8S(O)_2Cl$ in the presence of a base and in a suitable solvent; or
- ii. with an acid of formula R^7CO_2H in the presence of a suitable coupling agent in the presence of a suitable base in a suitable solvent.

8. A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier.

9. A compound of the formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, for use in therapy.

10. A compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1, in the manufacture of a medicament for use in therapy.

11. A method of treating a chemokine mediated disease state in a warm blooded animal suffering from, or at risk of, said disease, which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof as claimed in claim 1.